Key result
SP-8356 reduces brain infarct volume, improves acute neurological deficits, and lowers mortality in ischemic stroke.
Why the study?
Does SP-8356 reduce brain infarct volume and improve neurological deficits in a rat model of ischemic stroke?
Does SP-8356 reduce brain infarct volume and improve neurological deficits in a rat model of ischemic stroke?
Answers are grounded in this paper and cite their sources.
SP-8356 demonstrates multimodal cytoprotective effects, reducing infarct size and mortality in a rat model of ischemic stroke.
An ischemic cerebral stroke results from the interruption of blood flow to the brain, triggering rapid and complex cascades of excitotoxicity, oxidative stress, and inflammation. Current reperfusion therapies, including intravenous thrombolysis and mechanical thrombectomy, cause further brain injury due to reperfusion-induced cytotoxicity. To date, novel cytoprotective therapies that could address these challenges have yet to be developed, likely due to the limitations of targeting a single pathologic mechanism. To address these unmet clinical needs, we investigated a synthetic verbenone derivative, SP-8356, as a potential multi-target cytoprotective agent for acute ischemic strokes. In transient middle cerebral artery occlusion (MCAO) rats, SP-8356 significantly reduced brain infarct and edema volumes while improving acute neurological deficits in a dose-dependent manner. Furthermore, SP-8356 improved long-term outcomes, particularly by reducing mortality. These potent cytoprotective effects of SP-8356 were achieved by suppressing the excessive production of free radicals and pro-inflammatory cytokines, reducing the infiltration of inflammatory cells, and mitigating increases in blood-brain barrier permeability. Additional research is needed to determine whether co-administration of SP-8356 can extend the therapeutic time window of reperfusion therapies by mitigating ischemia/reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Song et al. (2024) studied Acute ischemic stroke. SP-8356 was evaluated on Brain infarct and edema volumes, acute neurological deficits, and mortality. SP-8356 significantly reduced brain infarct and edema volumes, improved acute neurological deficits, and reduced mortality in a transient MCAO rat model.
Synapse has enriched 10 related papers. Consider them for comparative context: